Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial

04 Mar 20265 min read0 viewsJournal Feed

GIST

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 04 Mar 2026. The item focuses on Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. Review the original article for the full source wording and details.

Clinical Editorial

Summary

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 04 Mar 2026.

The item focuses on Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.

Review the original article for the full source wording and details.